Gloucester Pharma Snags $29 Million Series D
This article was originally published in The Pink Sheet Daily
Executive Summary
As Gloucester Pharma preps for the FDA, the blood-borne cancer developer corrals a D round from Novo and others to gain leverage in partnering talks.
You may also be interested in...
Celgene Pays $340 Million For Gloucester And Its New Drug
Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.
Celgene Pays $340 Million For Gloucester And Its New Drug
Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.
Gloucester's Istodax Gains FDA Approval Ahead Of New Regulatory Requirements
With FDA's approval a week ahead of the PDUFA date, Gloucester Pharmaceuticals will bring its first product to market, the second HDAC inhibitor approved in cancer.